Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical device stocks to invest in right now. Barclays raised the price target on Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104 on April 27, reaffirming an Overweight rating on the shares. The rating update came after the company’s fiscal Q1 earnings, with the firm telling investors in a research note that Edwards Lifesciences Corporation’s quarter showed share gains in Europe and the United States.
In its financial results for Q1 released on April 23, Edwards Lifesciences Corporation reported that fiscal Q1 sales rose 16.7% to $1.65 billion, while constant currency sales grew 12.7%. TAVR sales in the quarter rose 14.4% to $1.20 billion, while constant currency sales grew 11.0%. The company further reported that fiscal Q1 TMTT sales reached $173 million, driven by repair and replacement therapies.
Edwards Lifesciences Corporation raised FY26 constant currency sales growth guidance to 9% to 11% from 8% to 10%, and also raised the FY26 adjusted EPS guidance midpoint, with a new range of $2.95 to $3.05 from $2.90 to $3.05.
Edwards Lifesciences Corporation is involved in patient-focused medical innovations for heart disease and critical care monitoring. The company’s products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. Its operations are divided into the following geographical segments: the United States, Europe, Japan, and the Rest of the World.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
